Bristol Myers Squibb (BMS) has partnered with Accenture to launch Mosaic in Mumbai, a generative AI–enabled content hub designed to transform biopharma marketing and commercialisation at a global scale. Positioned as a first-of-its-kind initiative, Mosaic aims to identify physicians’ educational needs in real time and rapidly develop patient-centric, personalised content, significantly strengthening BMS’s digital marketing and engagement capabilities worldwide.
The Mumbai-based hub represents a major step in BMS’s broader push toward data-driven and AI-led commercial transformation. By combining advanced generative AI tools with deep healthcare insights, Mosaic is intended to help the company deliver more relevant, timely, and impactful content to healthcare professionals across markets. The initiative aligns with BMS’s strategy to reimagine how scientific and educational information is created, localised, and delivered throughout the product lifecycle.
“The future of healthcare is about meeting clinicians and patients where they are and doing so in meaningful ways,” said Adam Lenkowsky, chief commercialisation officer at Bristol Myers Squibb, describing Mosaic as a key step in the company’s end-to-end digital transformation. The launch forms part of BMS’s wider $130 million investment in artificial intelligence across its marketing and commercial functions, reflecting a growing emphasis on technology-led innovation in the biopharma sector.
The Mosaic hub also builds on BMS’s long-standing and expanding footprint in India. In addition to the new Mumbai initiative, the company recently opened a major facility in Hyderabad that employs more than 3,000 professionals, underscoring India’s strategic importance in BMS’s global operations spanning technology, analytics, and digital services.
For Accenture, Mosaic marks the next phase of its 25-year partnership with Bristol Myers Squibb. The collaboration brings together Accenture’s creative, data, and technology expertise with BMS’s deep scientific and therapeutic knowledge to reimagine global content delivery for the biopharma industry. The Mumbai hub integrates teams across strategy, creative, AI engineering, and analytics to support faster turnaround times and greater consistency across global markets.
“Accenture and Bristol Myers Squibb are leading the AI forward reinvention of biopharma by applying innovative technologies to generate meaningful outcomes for patients,” said Ndidiamaka Oteh, CEO of Accenture Song.
As generative AI increasingly reshapes life sciences marketing, the Mosaic hub positions BMS and Accenture at the forefront of innovation, enabling scalable, personalised, and insight-driven engagement with clinicians and patients worldwide.
 has partnered with Accenture to launch Mosaic in Mumbai, a generative AI–enabled content hub designed to....){kind=link}